A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-03-13
Target enrollment:
Participant gender:
Summary
This study is about a medicine called TAK-788, also known as mobocertinib, given to adults
with non-small cell lung cancer.
The main aims of this study are to check if there are any side effects from TAK-788, to learn
how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this
condition.
Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take
TAK-788 unless they or their doctor decide they should stop this treatment.
Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea
prevention to determine the safety of TAK-788 treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ariad Pharmaceuticals Millennium Pharmaceuticals, Inc.